GoodRx Holdings, Inc. 8-K

What Happened

• GoodRx Holdings, Inc. (GDRX) filed an 8-K on March 18, 2026 announcing that, after a competitive proposal process, its board approved the appointment of KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved the dismissal of PricewaterhouseCoopers LLP (PwC).
• The filing states PwC’s audit reports on GoodRx’s consolidated financial statements for the years ended December 31, 2025 and 2024 were unqualified (no adverse or disclaimer opinions and no qualifications). There were no disagreements or reportable events with PwC for those years or through the interim period ended March 14, 2026.

Key Details

• Appointment effective for the fiscal year ending December 31, 2026: KPMG LLP named as independent auditor.
• Dismissal of PwC: PwC’s 2024 and 2025 audit reports were unmodified; no disagreements or reportable events noted through March 14, 2026.
• PwC provided a letter dated March 18, 2026 regarding the disclosures; that letter is filed as Exhibit 16.1 to the 8-K.
• The company and its representatives did not consult KPMG on accounting or auditing matters during 2024, 2025, or the interim period through March 14, 2026.

Why It Matters

• A change in independent auditor is a material corporate governance event: investors track it because auditors sign off on financial statements and audit transitions can affect timing or cost of audits.
• This filing highlights that PwC’s recent audits were unqualified and there were no disagreements or reportable events, which suggests the auditor change was procedural rather than prompted by audit disputes. Investors should watch future filings (e.g., audit fees, any restatements, or disclosures in the 2026 audit) for any material impact.